Cancer research
Buffalo's Roswell Park Comprehensive Cancer Center has been awarded a $100,000 grant from Hyundai Hope On Wheels, a nonprofit organization dedicated to finding a cure for childhood cancer. The award will fund research on CAR T-cell immunotherapy for pediatric acute lymphoblastic leukemia (ALL) led by Dr. Lisa
Cancer research
Researchers at the University of Miami Miller School of Medicine have made significant breakthroughs in the treatment of lymphoma, a type of cancer that affects the immune system. According to a recent study published in Cancer Research, the medical journal of the American Association for Cancer Research, the team has
Cancer
Cancer gene therapy has made significant advancements in recent years, with researchers exploring various methods to target and treat cancerous tumors. A new study from the University of Tabuk in Saudi Arabia has shed light on the potential of nanoparticles in stromal reprogramming, a process crucial for tumor expansion and
Cancer research
Researchers from Mashhad University of Medical Sciences have published a new study in the journal Drug Delivery, detailing the development of a novel strategy for enhancing the delivery of cancer gene therapy using nanoparticle-based delivery systems. The study focuses on the use of minoxidil-loaded nanoliposomes (Lip-MXD) to induce tumor vasodilation
Cancer
A clinical trial led by Dr. Michael Wong, a physician at Roswell Park Comprehensive Cancer Center, has shown promising results in treating advanced melanoma with a combination of RP1, an oncolytic virus, and nivolumab (Opdivo), an immunotherapy medication. The study, published in the Journal of Clinical Oncology, found that the
Cancer research
Physician scientist Anarkhuu Bold-Erdene, a doctoral student in radiation biology at Hiroshima University, recently completed a month-long internship at the Radiation Emergency Assistance Center/Training Site (REAC/TS) and the Cytogenetic Biodosimetry Laboratory (CBL) at the Oak Ridge Institute for Science and Education (ORISE). Bold-Erdene's research focuses on
Cancer research
Researchers at the National Cancer Center, Korea, are conducting a Phase 2 clinical trial to study the efficacy of lurbinectedin as a second-line treatment for high-grade pancreatic neuroendocrine tumors (pNETs). The trial aims to enroll 46 participants from the USA and is currently active but not open for recruiting. The
Cancer
Researchers at Xinxiang Medical University in Kaifeng, People's Republic of China, have shed light on the pivotal role of innate immunity in glioblastoma (GBM) pathogenesis. The study reviews the current understanding of innate immune mechanisms in GBM and explores novel combinatorial strategies to overcome therapeutic resistance in this
Cancer
Researchers at Warsaw University of Life Sciences have investigated the potential of liposomes and extracellular vesicles (EVs) in cancer gene therapy, particularly in glioblastoma multiforme (GBM). This aggressive subtype of glioma remains a significant clinical challenge due to its invasive nature and limited treatment options. The study highlights the complementary
Cancer
Research on cancer gene therapy has highlighted the potential of PAMAM dendrimers in enhancing the effectiveness of treatments. According to a recent study published in Pharmaceutics, these nanoparticles have shown the capacity for functionalization, which enhances their properties and renders them highly versatile. This has significant implications for their use
Cancer research
Researchers from the First Hospital of China Medical University in Shenyang, People's Republic of China, have made significant progress in understanding and addressing the challenge of cisplatin resistance in laryngeal cancer treatment. By identifying the role of tumor necrosis factor-alpha-induced protein 2 (TNFAIP2) in chemoresistance, the team developed
Cancer research
Scientists have made breakthroughs in using cutting-edge genetic technology to "personalize" cancer treatments. However, Health and Human Services Secretary Robert F. Kennedy, Jr.'s recent funding cuts for mRNA vaccines have sparked alarm among experts, who fear the decision will have a "profound chilling effect"
